Authors
Latest:
Understanding Social Toxicity as a New Measure in AML CareClaire Saxton, MBA, discusses findings from a study looking at social toxicity in acute myeloid leukemia.
Latest:
Practice Changing Updates in the EGFR+ and KRAS+ NSCLC SpaceAndreas Saltos, MD, discusses the current space for patients with non-small cell lung cancer harbording EGFR and KRAS mutations.
Latest:
World Lymphoma Awareness Day: More Drugs, Targets, and Hope in Non-Hodgkin LymphomaLee Greenberger, PhD, evaluates novel immunotherapies in non-Hodgkin lymphoma for World Lymphoma Awareness Day.
Latest:
Follicular Lymphoma: Forecasting Bispecific Antibody Treatment StrategiesClosing out their discussion on bispecific antibody therapies, Matthew Matasar, MD and Laurie Sehn, MD, consider ongoing clinical trials and real-world use of these novel agents.
Latest:
Key Takeaways Regarding Biomarker Testing for mNSCLCClosing thoughts from a panel of NSCLC experts, with an emphasis on improving access to and utilization of biomarker testing for patients with the disease.
Latest:
Studies in the Hepatocellular Carcinoma Space Leave Unanswered QuestionsAmaia Lujambio Goizueta, PhD, discusses the unanswered questions currently circulating the hepatocellular carcinoma field.
Latest:
Social Determinants of Health Should Be an Integral Component of Cancer Clinical TrialsThe COVID-19 pandemic has highlighted the marvels of rapid technologic advances while spotlighting the social issues that have been evident for decades but ignored and poorly addressed in many cases.
Latest:
The Future of Research in PEComasThe panel shares future areas of research in malignant PEComa that interest them, and how they see the treatment landscape evolving.
Latest:
AFM13 Plus AB-101 to Be Tested in Phase 2 StudyThe ongoing LuminICE phase 2 study demonstrated that AFM13 in combination with AB-101 may hold promise for the treatment of patients with relapsed or refractory CD30-positive lymphomas.
Latest:
Lung Cancer Screening Shown to Significantly Boost 20-Year Survival Rate in PatientsIn an early-intervention lung screening program, patients with lung cancer were found to have a survival rate nearly 20-times longer than patients with a late-stage diagnosis.
Latest:
Discussing Patient Characteristics in ESCC On Ipilimumab/NivolumabKen Kato, MD, PhD, discusses which patient characteristics to look out for when looking to put a patient on the combination of ipilimumab and nivolumab.
Latest:
Improved Safety Measures Mark Newest Treatments in Soft Tissue SarcomaIn early 2020, the treatment paradigm of soft tissue sarcoma had 3 notable advancements with the FDA approving therapies in epithelioid sarcoma, Kaposi sarcoma, and gastrointestinal stromal tumors.
Latest:
Looking Towards the Future of Molecular Testing and Additional Treatment Options for Patients with mNSCLCThe panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.
Latest:
Overall Survival Improved With 177 Lu-Dotatate for Patients With Progressive Midgut NETsFinal overall survival and long-term safety results of the phase 3 NETTER-1 trial were presented during the World Congress on Gastrointestinal Cancer 2021.
Latest:
Challenges Hinder Machine Learning's Potential in OncologyJames Zou, PhD, elaborates on some of the challenges associated with machine learning techniques and its utilization in oncology.
Latest:
Management of HR+, HER2- Early-Stage Breast Cancer After DiagnosisPhysicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.
Latest:
Real-World Data on Brexu-cel in Relapsed/Refractory B-Cell ALLIn an interview with Targeted Oncology, Evandro D. Bezerra, MD, discusses real-world findings of brexucabtagene autoleucel in relapsed/refractory B-cell ALL.
Latest:
Detecting and Addressing Hard-to-Find Skin CancersNiraj H. Mehta, MD, reviews the areas of the body where skin cancer can be hard to detect, what the skin cancer will look like on those parts of the body, risk factors for those receiving treatment, and follow-up for patients to catch recurrences.
Latest:
Expanding Allogeneic Stem Cell Transplantation for Relapsed and Refractory Acute Myeloid LeukemiaAllogeneic HCT has shown promise as definitive treatment for patients with relapsed or refractory AML.
Latest:
Future Research Aims to Examine Blocking STAT3 in Acute Myeloid LeukemiaMarcin Kortylewski, PhD, discusses what research he believes is next to come in the acute myeloid leukemia space.
Latest:
Individulizing Treatment and Exploring Options in Ovarian CancerChristina Fotopoulou, MD, PhD, discusses recent developments in ovarian cancer and explains how one can individualize treatments when managing patients.
Latest:
How Data Help Physicians Improve Operations and Achieve Health EquityA US health care executive survey found 30% see health equity solely as a social concern. Yet, it's about ensuring everyone has a fair shot at optimal health. Utilizing standardized data can shift care from reactive to preventive, easing strain on systems.
Latest:
Glioblastoma Treatment Is Slow to Change, but New Strategies Are Under InvestigationDuring the past 4 decades, glioblastoma has remained a cancer with one of the worst prognoses and is among the most debilitating.
Latest:
Final ThoughtsPanelists discuss how final thoughts emphasize the importance of ongoing research, collaborative care, and adapting treatment strategies to improve patient outcomes in the evolving therapy landscape.
Latest:
Steady Progress of AI Makes its Mark in the ClinicIncreasingly, and with exponential pace, AI algorithms are finding their way into the oncology clinic.
Latest:
EP. 2B: Challenges Affecting the Management of Extensive-Stage Small Cell Lung CancerIn this companion article, Dr. Jared Weiss provides key insights into recent advancements in the standard of care for extensive-stage small cell lung cancer and examines challenges affecting treatment.
Latest:
Key Takeaways from SABCS 2023 in HER2+ Breast CancerFollowing their review of clinical trial data presented at SABCS 2023, the Oncology Brothers discuss their key takeaways on recent updates in HER2+ breast cancer.
